【摘要】：目的:通過(guò)觀察放化療聯(lián)合復(fù)方苦參注射液治療宮頸癌臨床療效及對(duì)患者細(xì)胞免疫功能及生活質(zhì)量影響,從而為臨床宮頸癌患者治療提供有力依據(jù)。方法:按照隨機(jī)數(shù)字表法將診斷為80例Ⅲa~Ⅳ期宮頸癌患者分組為對(duì)照組與治療組,各40例。對(duì)照組采用放化療治療;治療組于放化療治療基礎(chǔ)上加用復(fù)方苦參注射液治療;28 d為1個(gè)周期,2組均治療3個(gè)周期。于治療前及治療后第2天檢測(cè)2組患者細(xì)胞免疫功能,統(tǒng)計(jì)2組患者臨床療效、生活質(zhì)量、不良反應(yīng)。結(jié)果:經(jīng)治療3個(gè)周期后,治療組CD3+、CD4+、NK細(xì)胞及CD4+/CD8+值較治療前明顯提高,而CD8+值較治療前明顯下降,且優(yōu)于對(duì)照組,P0.05;對(duì)照組CD8+及NK細(xì)胞數(shù)較治療前稍增加,其他指標(biāo)較治療前略下降,P0.05。治療組總有效者19例(總有效率為47.5%)明顯高于對(duì)照組13例(32.5%),P0.05。治療組生存質(zhì)量改善者為37例(改善率為92.5%)明顯高于對(duì)照組29例(72.5%),P0.05;治療組不良反應(yīng)率明顯低于對(duì)照組,P0.05。結(jié)論:應(yīng)用復(fù)方苦參注射液聯(lián)合放化療治療宮頸癌,其可減少不良反應(yīng),增強(qiáng)患者細(xì)胞免疫功能,從而提高臨床療效及患者生活質(zhì)量。
[Abstract]:Objective: to observe the clinical efficacy of radiotherapy and chemotherapy combined with compound Sophora flavescens injection in the treatment of cervical cancer and its effect on cellular immune function and quality of life, so as to provide a powerful basis for the treatment of cervical cancer. Methods: according to the random digital table method, 80 patients with stage III a ~ IV cervical cancer were divided into control group (n = 40) and treatment group (n = 40). The control group was treated with radiotherapy and chemotherapy, and the treatment group was treated with compound Sophora flavescens injection on the basis of radiotherapy and chemotherapy. 28 days was one cycle, and both groups were treated for 3 cycles. The cellular immune function of the two groups was measured before and 2 days after treatment, and the clinical efficacy, quality of life and adverse reactions of the two groups were counted. Results: after three cycles of treatment, the values of CD3, CD4, NK cells and CD4 / CD8 in the treatment group were significantly higher than those before treatment, while the values of CD8 were significantly lower than those before treatment, and were better than those in the control group (P0.05). The number of CD8 and NK cells in the control group was slightly higher than that before treatment, and the other indexes were slightly lower than those before treatment (P0.05). The total effective rate in the treatment group (47.5%) was significantly higher than that in the control group (32.5%). The improvement rate of quality of life in the treatment group (92.5%) was significantly higher than that in the control group (72.5%), P0.05, and the adverse reaction rate in the treatment group was significantly lower than that in the control group (P0.05). Conclusion: the treatment of cervical cancer with compound Sophora flavescens injection combined with radiotherapy and chemotherapy can reduce the adverse reactions and enhance the cellular immune function of the patients, so as to improve the clinical efficacy and quality of life of the patients.
【作者單位】： 武警浙江總隊(duì)杭州醫(yī)院腫瘤科;
【分類號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前8條

1 王雪琴;茅敏;;復(fù)方苦參注射液對(duì)宮頸癌化療患者免疫功能影響[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2014年24期

2 王永斌;賴彪生;羅惠煌;;復(fù)方苦參注射液聯(lián)合三維適形放療治療復(fù)發(fā)性宮頸癌療效觀察[J];醫(yī)學(xué)信息(中旬刊);2011年09期

3 王國(guó)慶;趙西俠;周敏;王勤;金素娟;營(yíng)明娟;;復(fù)方苦參注射液減輕婦科腫瘤盆腔放射性損傷的臨床觀察[J];臨床腫瘤學(xué)雜志;2011年04期

4 鄭玉霞;;復(fù)方苦參注射液聯(lián)合化療治療宮頸癌的臨床觀察[J];河南外科學(xué)雜志;2010年04期

5 張文謹(jǐn);彭瑤;連增林;靳冉;李晉生;海麗娜;;復(fù)方苦參注射液對(duì)人子宮內(nèi)膜癌細(xì)胞HEC-1B雌激素受體表達(dá)的影響[J];中國(guó)中醫(yī)藥信息雜志;2012年05期

6 陳芳;黃小陸;梁林;;復(fù)方苦參注射液對(duì)人宮頸癌細(xì)胞株Hela的體外放射增敏作用[J];廣東醫(yī)學(xué);2011年07期

7 張文謹(jǐn);彭瑤;連增林;靳冉;李晉生;海麗娜;;復(fù)方苦參注射液對(duì)子宮內(nèi)膜癌HEC-1B細(xì)胞Bcl-2/Bax、P27表達(dá)的影響[J];天津中醫(yī)藥大學(xué)學(xué)報(bào);2012年02期

8 ;[J];;年期

相關(guān)碩士學(xué)位論文 前1條

1 陳芳;中成藥復(fù)方苦參注射液對(duì)離體人宮頸癌細(xì)胞的放射增敏作用[D];南昌大學(xué);2007年

，

本文編號(hào)：2517904